ArticleO&G open2025
Updates in the Management of Malignant Ovarian Germ Cell Tumors.
Article in O&G open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Laparoscopic Surgery for Pediatric Malignant Ovarian Germ Cell Tumors After Neoadjuvant Chemotherapy: A Single-Center Retrospective Study.Journal of clinical medicine · 2026Article
- First-trimester ovarian dysgerminoma in pregnancy: a case report highlighting the value of expert ultrasound.Frontiers in oncology · 2026Article
- Receptor Co‑targeting Strategies for Personalized Ovarian Cancer Therapy.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant ovarian germ cell tumors are rare malignancies primarily affecting adolescents and young adults. Management must balance curative intent with fertility preservation. This review highlights recent advances in malignant ovarian germ cell tumor management, focusing on risk-stratified approaches, surgical techniques, somatic transformation, and long-term surveillance. The bleomycin/etoposide/cisplatin regimen remains the first-line therapy. Fertility-sparing surgery, including unilateral salpingo-oophorectomy with minimal staging, is recommended for adolescent and young adult patients. Chemotherapy is not recommended for those with surgically resected immature teratomas. In advanced-stage malignant ovarian germ cell tumors, adjuvant chemotherapy may be considered for frail patients with chemosensitive tumors. Given the risk of late complications, long-term surveillance and lifelong care are essential for survivors. Future directions emphasize molecular profiling to guide personalized treatment. Multidisciplinary care, precision surgery, and tailored systemic therapies continue to improve survival while preserving quality of life. Collaborative trials are crucial for standardizing salvage approaches and mitigating long-term toxicities, ensuring optimal outcomes for this young, survivorship-focused population.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.